Lupin’s wholly-owned Japanese subsidiary -- Kyowa Pharmaceutical Industry, is planning to set up a manufacturing plant at Tottori, Japan as part of expansion plans in the country. In order to meet the rapidly growing demand of generics, the company is planning to set-up two billion tablets capacity plant at Tottori, Japan which would be designed to efficiently handle mass volume products and provide flexibility in allowing easy future expansion.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.
